📣 VC round data is live. Check it out!
- Public Comps
- XtalPi
XtalPi Valuation Multiples
Discover revenue and EBITDA valuation multiples for XtalPi and similar public comparables like Shenzhen Intellifusion, Caris Life Sciences, Lemonade, UiPath and more.
XtalPi Overview
About XtalPi
XtalPi Holdings Ltd is an research platform company powered by artificial intelligence (AI) and robotics. It is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. The company combines quantum physics, AI, cloud computing, and large-scale robotics to provide research & development solutions, services, and products for pharmaceuticals, biotechnology, renewable energy, and materials industries globally. The company has single segment that is intelligent robotics solutions and drug discovery solutions (including one-stop drug discovery solutions).
Founded
2017
HQ

Employees
809
Website
Sectors
Financials (LTM)
EV
$4B
Valuation Multiples
Start free trialXtalPi Financials
XtalPi reported last 12-month revenue of $126M and negative EBITDA of ($15M).
In the same LTM period, XtalPi generated $83M in gross profit, ($15M) in EBITDA losses, and $16M in net income.
Revenue (LTM)
XtalPi P&L
In the most recent fiscal year, XtalPi reported revenue of $118M and EBITDA of $38M.
XtalPi is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 32%, and net margin of 17%.
Financial data powered by Morningstar, Inc.
XtalPi Stock Performance
XtalPi has current market cap of $5B, and enterprise value of $4B.
Market Cap Evolution
XtalPi's stock price is $1.14.
XtalPi share price decreased by 6.0% in the last 30 days, and increased by 94.8% in the last year.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $5B | -4.1% | -6.0% | -13.5% | 94.8% | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialXtalPi Valuation Multiples
XtalPi trades at 31.4x EV/Revenue multiple, and (256.8x) EV/EBITDA.
EV / Revenue (LTM)
XtalPi Financial Valuation Multiples
As of May 8, 2026, XtalPi has market cap of $5B and EV of $4B.
XtalPi has a P/E ratio of 305.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified XtalPi Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


XtalPi Margins & Growth Rates
XtalPi grew revenue by 22% but EBITDA decreased by 118% in the last fiscal year.
In the most recent fiscal year, XtalPi reported gross margin of 70%, EBITDA margin of 32%, and net margin of 17%.
XtalPi Margins
XtalPi Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
XtalPi Operational KPIs
XtalPi's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
XtalPi's Rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
XtalPi's Rule of X is 51% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
XtalPi Competitors
XtalPi competitors include Shenzhen Intellifusion, Caris Life Sciences, Lemonade, UiPath, Intsig Information, Presight AI, SoundHound, Hinge Health, Fermi and Privia Health.
Most XtalPi public comparables operate across Health Data & Analytics, Vertical AI Applications, Artificial Intelligence, B2B SaaS, Horizontal SaaS, DeepTech, HealthTech and Quantum Computing.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 22.4x | — | (1856.9x) | — | |||
| 6.1x | 5.7x | 36.2x | 34.0x | |||
| 5.7x | 4.7x | (35.7x) | (43.9x) | |||
| 2.6x | 2.6x | 11.1x | 10.7x | |||
| 14.0x | 12.8x | 43.6x | 43.2x | |||
| 6.1x | 5.7x | 23.7x | 21.8x | |||
| 21.6x | 19.1x | 128.4x | (84.5x) | |||
| 6.3x | 5.6x | 30.5x | 24.5x | |||
This data is available for Pro users. Sign up to see all XtalPi competitors and their valuation data. Start Free Trial | ||||||
XtalPi Funding History
Before going public, XtalPi raised $786M in total equity funding, across 7 rounds.
Last private valuation of XtalPi was $2B, after raising $400M in August 2021 from 5Y Capital, HOPU Investment Management Company, HSG, and 3 other investors.
XtalPi Funding Rounds
XtalPi M&A Activity
XtalPi has acquired 1 company to date.
Last acquisition by XtalPi was on June 13th 2025. XtalPi acquired Liverpool ChiroChem for undisclosed valuation.
Latest Acquisitions by XtalPi
| Description | Liverpool ChiroChem is a contract research organization specializing in chiral small molecules for drug discovery. Liverpool, UK-headquartered LCC supplies building blocks, fragments, and screening compounds like chiral piperidines via asymmetric hydrogenation and Pd-coupling. The firm collaborates on synthetic route optimization for biotech and pharma R&D. |
| HQ Country | |
| HQ City | Liverpool |
| Deal Date | 13 Jun 2025 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all XtalPi acquisitions and their M&A valuation multiples. Start Free Trial | |
XtalPi Investment Activity
XtalPi has invested in 10 companies to date.
Latest investment by XtalPi was on April 1st 2026. XtalPi invested in Xellar Biosystems in their $29M Series A round (EV/Revenue multiple of ).
Latest Investments by XtalPi
| Description | Xellar Biosystems is a biotechnology company developing wet artificial intelligence platforms for drug testing and treatment analysis. Its solutions integrate lab-on-a-chip technologies with machine learning to evaluate compound efficacy in real-time cellular environments. Based in Boston, the firm targets pharmaceutical research for faster iteration in oncology and infectious disease pipelines. Xellar partners with contract research organizations to validate its assays against traditional high-throughput screening methods. | Dingxi Zhichuang is an integrated circuit chip developer that designs, manufactures, and sells chips, products, and semiconductor equipment. | Deepin Technology is a Shanghai-based provider of artificial intelligence platforms for chemical materials research. The company integrates quantum chemistry simulations, high-throughput screening, and machine learning to accelerate molecule discovery and property prediction. Its Deep Principle platform supports virtual screening of millions of compounds daily and generative design for novel materials. Deepin Technology serves industries including pharmaceuticals, batteries, and semiconductors, with tools deployed in over 100 research labs across Asia. Founded in 2021, it collaborates with institutions like the Chinese Academy of Sciences. | Newdel Biotech is a China-based provider of drug discovery screening, biomedical R&D, and consulting services for pharmaceutical development. | |
| HQ Country | |||||
| HQ City | Boston, MA | Shenzhen | Beijing | — | |
| Deal Date | 1 Apr 2026 | 24 Mar 2026 | 3 Mar 2026 | 21 Jan 2026 | |
| Round | Series A | Angel | Series A | Series A | |
| Raised | $29M | undisclosed | undisclosed | undisclosed | |
| Investors | China Life Private Equity Investment; Legend Capital; XtalPi; Yael Capital Management Limited | Shanghai Future Industry Fund; XtalPi | Baidu Ventures; Golden Ant Investment; Inspiration Capital; XtalPi | XtalPi | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all XtalPi investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout XtalPi
| When was XtalPi founded? | XtalPi was founded in 2017. |
| Where is XtalPi headquartered? | XtalPi is headquartered in China. |
| How many employees does XtalPi have? | As of today, XtalPi has over 809 employees. |
| Who is the CEO of XtalPi? | XtalPi's CEO is Jian Ma. |
| Is XtalPi publicly listed? | Yes, XtalPi is a public company listed on HKEX. |
| What is the stock symbol of XtalPi? | XtalPi trades under 02228 ticker. |
| When did XtalPi go public? | XtalPi went public in 2024. |
| Who are competitors of XtalPi? | XtalPi main competitors include Shenzhen Intellifusion, Caris Life Sciences, Lemonade, UiPath, Intsig Information, Presight AI, SoundHound, Hinge Health, Fermi, Privia Health. |
| What is the current market cap of XtalPi? | XtalPi's current market cap is $5B. |
| What is the current revenue of XtalPi? | XtalPi's last 12 months revenue is $126M. |
| What is the current revenue growth of XtalPi? | XtalPi revenue growth (NTM/LTM) is 30%. |
| What is the current EV/Revenue multiple of XtalPi? | Current revenue multiple of XtalPi is 31.4x. |
| Is XtalPi profitable? | No, XtalPi is not profitable. |
| What is the current EBITDA of XtalPi? | XtalPi has negative EBITDA and is not profitable. |
| What is XtalPi's EBITDA margin? | XtalPi's last 12 months EBITDA margin is (12%). |
| What is the current EV/EBITDA multiple of XtalPi? | Current EBITDA multiple of XtalPi is (256.8x). |
| How many companies XtalPi has acquired to date? | As of May 2026, XtalPi has acquired 1 company. |
| What was the largest acquisition by XtalPi? | None of the M&A deals XtalPi has completed have disclosed valuations. |
| What companies XtalPi acquired? | XtalPi acquired Liverpool ChiroChem. |
| In how many companies XtalPi has invested to date? | As of May 2026, XtalPi has invested in 10 companies. |
| What was the last XtalPi investment? | On 1st April 2026 XtalPi invested in Xellar Biosystems, participating in a $29M Series A round, alongside China Life Private Equity Investment, Legend Capital, and Yael Capital Management Limited. |
| In what companies XtalPi invested in? | XtalPi invested in PhoreMost, ReviR Therapeutics, Xellar Biosystems, META Pharmaceuticals, Signet Therapeutics, Leman Biotech, CytoCan Corp., Dingxi Zhichuang, Deepin Technology, and Newdel Biotech. |
See public comps similar to XtalPi
Lists including XtalPi
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


